Loading AKUMS price...
Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 8 Aug 2026), sales rose 13.9% from a year earlier to Rs 1,167 cr and profit rose 56.1% to Rs 101 cr.
Nothing in the filings we hold crosses one of our rules yet. Each rule needs a few complete years of results, so recently listed companies often show nothing here.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 8 results, the share rose on 2 and fell on 6, and moved by 3% or more on 5.
Q1 FY27: results filed 8 Aug 2026. The share went from its close on 7 Aug 2026 to its close on 10 Aug 2026 +4.68%.
At FY26 it owned Rs 5,447 Cr of assets. Its owners funded 61% of that and borrowings 1%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 1,181 Cr, spent Rs 231 Cr on plant and equipment, and cash rose by Rs 285 Cr over the year.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.19 L cr | 34.7x | 5.0x | 14.4% | 17.9% | 0.05 | 20.2% | +10.5% | 0.94% |
| DIVISLAB Divi's Laboratories Limited | 2.37 L cr | 81.2x | 14.2x | 17.4% | 19.0% | 0.00 | 26.1% | +27.8% | 0.34% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.72 L cr | 76.4x | 9.4x | 11.4% | - | 0.76 | 12.1% | +50.8% | 0.75% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.13 L cr | 25.2x | 4.2x | 15.5% | 19.2% | 0.40 | 16.1% | +22.0% | 0.98% |
| CIPLA Cipla Limited | 1.08 L cr | 32.1x | 3.1x | 9.7% | 14.9% | 0.01 | 11.8% | +2.3% | 1.20% |
| LAURUSLABS Laurus Labs Limited | 1.06 L cr | 97.4x | 20.1x | 20.1% | 19.7% | 0.44 | 15.0% | +29.1% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.03 L cr | 36.6x | 2.6x | 7.0% | - | 0.15 | 8.3% | -1.5% | 0.65% |
| MANKIND Mankind Pharma Limited | 91,380 cr | 44.8x | 5.6x | 12.5% | 13.7% | 0.38 | 14.0% | +12.9% | 0.05% |
| AUROPHARMA Aurobindo Pharma Limited | 90,436 cr | 24.6x | 2.4x | 9.8% | 13.6% | 0.20 | 10.6% | +16.3% | 0.26% |
| LUPIN Lupin Limited | 88,199 cr | 16.0x | 3.9x | 24.7% | 28.4% | 0.26 | 18.5% | +32.0% | 0.62% |
| GLENMARK Glenmark Pharmaceuticals Limited | 61,141 cr | 34.0x | 5.8x | 17.1% | 16.2% | 0.00 | 10.1% | +23.1% | 0.23% |
| ALKEM Alkem Laboratories Limited | 59,141 cr | 27.4x | 4.3x | 15.4% | 18.8% | 0.11 | 14.6% | +10.9% | 1.04% |
| BIOCON Biocon Limited | 52,718 cr | 95.7x | 1.6x | 1.1% | 2.9% | 0.40 | 2.4% | +10.0% | 0.17% |
| IPCALAB IPCA Laboratories Limited | 49,555 cr | 37.8x | 6.2x | 14.4% | 16.4% | 0.07 | 13.6% | +20.8% | 0.11% |
| GLAND Gland Pharma Limited | 46,631 cr | 41.3x | 4.5x | 10.9% | 13.7% | 0.02 | 16.8% | +19.6% | 0.64% |
| AJANTPHARM Ajanta Pharma Limited | 41,164 cr | 36.2x | 9.1x | 25.1% | 29.4% | 0.05 | 19.6% | +24.8% | 0.85% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 40,738 cr | 38.1x | 18.0x | 46.8% | 55.4% | 0.00 | 27.0% | +16.6% | 1.75% |
| EMCURE Emcure Pharmaceuticals Limited | 33,581 cr | 33.2x | 6.8x | 20.5% | 25.1% | 0.24 | 10.5% | +22.9% | 0.17% |
| SAILIFE Sai Life Sciences Limited | 29,621 cr | 82.4x | 11.9x | 14.6% | 18.1% | 0.04 | 16.1% | +11.7% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 29,188 cr | 71.5x | 5.9x | 7.8% | 6.5% | 0.40 | 11.6% | +25.9% | 0.00% |
| PPLPHARMA Piramal Pharma Limited | 25,362 cr | - | 3.1x | -3.8% | 0.8% | 0.67 | -3.4% | +17.4% | 0.07% |
| NEULANDLAB Neuland Laboratories Limited | 24,337 cr | 48.6x | 13.0x | 26.6% | 23.1% | 0.10 | 21.0% | +119.2% | 0.06% |
| RUBICON Rubicon Research Limited | 23,557 cr | 81.1x | 18.3x | 22.4% | 24.3% | 0.20 | 14.9% | - | 0.00% |
| GRANULES Granules India Limited | 19,694 cr | 29.5x | 3.9x | 13.0% | 16.0% | 0.26 | 11.8% | +22.0% | 0.18% |
| COHANCE Cohance Lifesciences Limited | 17,211 cr | 112.2x | 4.4x | 2.6% | 4.8% | 0.04 | 3.9% | -23.1% | 0.00% |
| SHILPAMED Shilpa Medicare Limited | 16,906 cr | 56.6x | 6.5x | 11.5% | 12.4% | 0.25 | 17.7% | +44.9% | 0.06% |
| CAPLIPOINT Caplin Point Laboratories Limited | 16,887 cr | 25.5x | 4.7x | 18.7% | 22.0% | 0.00 | 29.6% | +19.6% | 0.27% |
| PFIZER Pfizer Limited | 16,526 cr | 30.3x | 3.9x | 17.5% | 22.9% | 0.00 | 28.6% | +8.3% | 4.55% |
| ALIVUS Alivus Life Sciences Limited | 15,350 cr | 25.5x | 4.6x | 18.1% | 21.8% | 0.00 | 23.3% | +6.4% | 0.40% |
| ONESOURCE Onesource Specialty Pharma Limited | 15,294 cr | - | 2.6x | -0.8% | 0.5% | 0.22 | -3.1% | +37.2% | 0.00% |
| ERIS Eris Lifesciences Limited | 15,184 cr | 23.3x | 3.9x | 17.1% | 15.7% | 0.59 | 20.6% | +13.0% | 0.00% |
| ASTRAZEN AstraZeneca Pharma India Limited | 14,971 cr | 172.4x | 17.1x | 19.4% | 25.5% | 0.00 | 7.0% | +29.7% | 0.53% |
| APLLTD Alembic Pharmaceuticals Limited | 14,940 cr | 21.6x | 2.6x | 12.2% | 12.8% | 0.24 | 8.9% | +25.7% | 1.45% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,825 cr | 42.3x | 2.1x | 5.0% | 6.4% | 0.45 | 4.1% | +17.3% | 0.54% |
| NATCOPHARM Natco Pharma Limited | 14,174 cr | 12.4x | 1.5x | 12.4% | 16.3% | 0.08 | 32.9% | -44.7% | 0.64% |
| MARKSANS Marksans Pharma Limited | 13,001 cr | 25.1x | 4.3x | 17.1% | 17.5% | 0.01 | 16.4% | +35.6% | 0.28% |
| CONCORDBIO Concord Biotech Limited | 12,860 cr | 47.1x | 6.4x | 13.5% | 16.6% | 0.00 | 24.6% | +26.2% | 0.87% |
| ACUTAAS Acutaas Chemicals Limited | 12,844 cr | 66.8x | 7.8x | 22.6% | 27.7% | 0.02 | 26.5% | +59.1% | 0.10% |
| CORONA CORONA Remedies Limited | 12,545 cr | 63.0x | 16.8x | 26.6% | 29.3% | 0.19 | 13.5% | - | 0.00% |
| AKUMS Akums Drugs and Pharmaceuticals Limited | 10,243 cr | 35.1x | 3.1x | 8.8% | 10.9% | 0.02 | 6.5% | +13.9% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Each bar is one quarter as filed with the exchange, newest on the right, so the seasonal shape of the business is visible rather than smoothed away. Hover any quarter for its full figures and the change against the same quarter a year earlier. Revenue and profit are drawn on separate scales because they differ by an order of magnitude; reading one against the other would be misleading.
2026 has paid Rs 2.00 per share, about Rs 299 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.